Ninlib 150mg Capsule

About

Ninlib 150mg Capsule is a novel oral targeted therapy specifically engineered to inhibit crucial molecular pathways that drive cancer cell growth, proliferation, and survival. Functioning as a multi-kinase inhibitor, it effectively blocks several receptor tyrosine kinases, including those involved in angiogenesis, cell cycle progression, and metastatic spread. By disrupting these vital signaling cascades, Ninlib aims to halt tumor progression, induce programmed cell death (apoptosis) in malignant cells, and potentially reduce tumor size, while striving to minimize adverse effects on healthy tissues. This selective mechanism of action positions Ninlib as a promising and precise treatment option for various advanced solid tumors, offering a more targeted and personalized approach to cancer management for eligible patients.

Uses

• Treatment of advanced solid tumors resistant to conventional therapies.
• Management of specific types of metastatic cancer.
• As a second-line therapy for certain refractory malignancies.
• In combination with other agents for enhanced anti-tumor activity.

Directions For Use

Take Ninlib 150mg Capsule orally once daily, at approximately the same time each day, with or without food, as prescribed by your physician. Swallow the capsule whole; do not open, crush, or chew.

Benefits

• Targets multiple pathways critical for cancer growth.
• Offers a treatment option for advanced or refractory cancers.
• May improve progression-free survival in eligible patients.
• Oral administration provides convenience for patients.
• Part of a personalized medicine strategy.
• Potential to reduce tumor burden and disease progression.

Side Effects

• Fatigue
• Nausea
• Diarrhea
• Vomiting
• Rash
• Hand-foot syndrome
• Hypertension
• Anorexia
• Headache
• Liver enzyme abnormalities
• Proteinuria
• Hemorrhage

Safety Measures

• Alcohol - Limit alcohol intake during treatment, as it may increase the risk of certain side effects, particularly liver-related issues.
• Pregnancy - Ninlib may cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for a specified period after the last dose.
• Breastfeeding - It is not known if Ninlib is excreted in human milk. Due to the potential for serious adverse reactions in infants, breastfeeding is not recommended during treatment.
• Liver - Use with caution in patients with hepatic impairment. Liver function tests should be monitored regularly, and dose adjustments may be necessary.
• Kidney - Dose adjustments may be required for patients with moderate to severe renal impairment. Renal function should be assessed before and during therapy.
• Lung - Monitor for new or worsening respiratory symptoms, as interstitial lung disease or pneumonitis can be rare but serious side effects with some targeted therapies.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.